National Asset Management Inc. lessened its stake in 23andMe Holding Co. (NASDAQ:ME – Get Rating) by 36.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,180 shares of the company’s stock after selling 9,088 shares during the quarter. National Asset Management Inc.’s holdings in 23andMe were worth $62,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Exos Asset Management LLC boosted its holdings in shares of 23andMe by 21.4% in the first quarter. Exos Asset Management LLC now owns 21,636 shares of the company’s stock valued at $83,000 after buying an additional 3,811 shares during the period. Steward Partners Investment Advisory LLC boosted its holdings in 23andMe by 262.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,433 shares of the company’s stock worth $36,000 after purchasing an additional 3,933 shares during the last quarter. Stratos Wealth Partners LTD. boosted its holdings in 23andMe by 14.3% during the first quarter. Stratos Wealth Partners LTD. now owns 34,695 shares of the company’s stock worth $133,000 after purchasing an additional 4,345 shares during the last quarter. Commonwealth Equity Services LLC boosted its holdings in 23andMe by 36.2% during the fourth quarter. Commonwealth Equity Services LLC now owns 20,957 shares of the company’s stock worth $139,000 after purchasing an additional 5,570 shares during the last quarter. Finally, Kestra Advisory Services LLC boosted its holdings in 23andMe by 39.3% during the fourth quarter. Kestra Advisory Services LLC now owns 20,241 shares of the company’s stock worth $135,000 after purchasing an additional 5,710 shares during the last quarter. Institutional investors and hedge funds own 14.14% of the company’s stock.
Wall Street Analyst Weigh In
ME has been the subject of several recent research reports. Credit Suisse Group reduced their target price on shares of 23andMe from $11.00 to $7.00 and set an “outperform” rating for the company in a report on Friday, May 27th. Citigroup reduced their target price on shares of 23andMe from $6.00 to $3.00 and set a “neutral” rating for the company in a report on Friday, May 27th.
23andMe Trading Up 0.4 %
23andMe (NASDAQ:ME – Get Rating) last posted its quarterly earnings results on Thursday, May 26th. The company reported -0.13 earnings per share (EPS) for the quarter. 23andMe had a negative return on equity of 25.41% and a negative net margin of 79.99%. The firm had revenue of 100.56 million for the quarter, compared to the consensus estimate of 102.79 million. The firm’s quarterly revenue was up 13.5% compared to the same quarter last year.
23andMe Holding Co operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit.
- Get a free copy of the StockNews.com research report on 23andMe (ME)
- MarketBeat Podcast: Find Investing Opportunities For The Rest of 2022
- The Colgate-Palmolive Growth Outlook Brightens
- Deep Value High Yield Newell Brands Is Ready To Bottom
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian’s Stock Still Have A Future?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for 23andMe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 23andMe and related companies with MarketBeat.com's FREE daily email newsletter.